Rather version FigShare clinical database ILC – vs. 150206
Variables
patient_id:
consortium_label:
biobank:
patient_cohort:
year_of_diagnosis:
first_local_recurrence:
first_regional_recurrence:
first_distant_recurrence:
time_to_last_follow_up
status_at_last_follow_up
tumour_size_in _cm
number_of_positive_lymph_nodes
pathologic_m1_stage_at _diagnosis
treatment_surgery
treatment_hormonal
treatment_adjuvant_chemotherapy
treatment_radiotherapy
breast_cancer_specific_survival_time
breast_cancer_specific_survival_event
recurrence_free_survival_time
recurrence_free_survival_time
distant_recurrence_free_survival_time
distant_recurrence_free_survival_event
only_rfs_os_analysis
exclude_for_all_survival
age_at_diagnosis
comments
histologic_subtype
grade
ER.ihc
PR.ihc
Rather database patient id
Sample name
Source
Inclusion cohort
Year of diagnosis
number of days between diagnosis and first local
recurrence
Number of days between diagnosis and first
regional recurrence
Number of days between diagnosis and first
distant recurrence
Number of days between diagnosis and date of
last follow-up
Patient status at end of follow-up
Tumour size in cm
Number of tumour positive lymph nodes after
surgery
Pathologic M stage after surgery
Surgical Treatment
Hormonal therapy
Adjuvant chemotherapy treatment
Radiotherapy treatment
Number of days between last follow-up and
diagnosis date
Status at end of follow-up is dead-diseasespecific
Number of days between minimum of first local,
regional, distant recurrence or last follow-up
Either local, regional, distant recurrence or deaddisease-specific status at last follow-up
Number of days between
first_distant_recurrence or last follow-up
Either distant recurrence or dead-diseasespecific status at last follow-up
Patient should be excluded for anything but
Overall and Disease Free Survival analysis
Patient should be excluded for all survival
analyses
Diagnosis date – date of birth rounded down
Remarks on specific characteristics or
associations between samples
Histological subtyping
Histological grade of the tumor
ER immunohistochemistry positive/negative
(cutoff < 10 vs. =>10)
PR immunohistochemistry positive/negative
(cutoff < 10 vs. =>10)
HER2.ihc
HER2 immunohistochemistry (intensity 0,1 =
negative, 2 is uncertain, 3= positive)